Blog
RSS FeedPosted by Michael Wonder on 20 Nov 2022
PHARMAC welcomes Myeloma NZ as first patient advocacy group to present to PTAC
21 November 2022 - Myeloma New Zealand presented directly to PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC) on Thursday, making ...
Posted by Michael Wonder on 22 Oct 2022
Patient centred health technology assessment: a perspective on engagement in health technology assessment by three patient organisations and a health technology assessment body
20 October 2022 - Patient engagement in health technology assessment has become increasingly important over the past 20 years. ...
Posted by Michael Wonder on 04 Aug 2022
The patient voice – the value of patient-reported outcomes in HTA
4 August 2022 - The patient’s voice is increasingly important in securing access for therapies in markets and demonstrating how ...
Posted by Michael Wonder on 02 Aug 2022
FDA official: patients play an increasing role in rare disease drug development
1 August 2022 - Patients have a critical role in drug development, from identifying unmet medical needs to assessing meaningful ...
Posted by Michael Wonder on 24 Mar 2022
Pressured by patients, FDA reviews ALS drug with modest data
25 March 2022 - The FDA meets next week to review a closely watched drug for ALS, or Lou Gehrig’s ...
Posted by Michael Wonder on 07 Feb 2022
Mentoring as a potential means to assist consumer representatives contribute effectively to the assessment of health technologies in Australia: a pragmatic review
7 February 2022 - This project was implemented on behalf of the Health Technology Assessment Consumer Consultative Committee to explore training ...
Posted by Michael Wonder on 07 Feb 2022
Analysis of consumer comments into PBAC decision-making (2014–9)
4 February 2022 - Our objective was to analyse and review consumer comments in the PBAC's decision-making process. ...
Posted by Michael Wonder on 20 Oct 2021
Bringing a consumer perspective to clinical advice
19 October 2021 - PHARMAC is making changes to the way its advisory committees work to strengthen the input of ...
Posted by Michael Wonder on 09 Sep 2021
Consumers to have more say on medicine access issues
7 September 2021 - Consumer involvement in Australia’s medicines choices has been further strengthened under a new strategic agreement Medicines ...
Posted by Michael Wonder on 04 Aug 2021
How to balance the patient voice atop the shifting plates of HTA
3 August 2021 - The tectonic plates of healthcare technology assessment have shifted – but where does the patient voice ...
Posted by Michael Wonder on 25 Jul 2021
Patient advocacy organisations and FDA drug approval: lessons from Aduhelm
23 July 2021 - In the wake of last month’s controversial FDA approval of Biogen’s Aduhelm, Alzheimer’s Association CEO Harry ...
Posted by Michael Wonder on 18 Jul 2021
How to integrate evidence from patient preference studies into health technology assessment: a critical review and recommendations
15 July 2021 - Health technology assessment agencies vary in their use of quantitative patient preference data and the extent to ...
Posted by Michael Wonder on 06 Jul 2021
MHRA outlines two year delivery plan with ‘patient first’ focus
6 July 2021 - The UK’s Medicines and Healthcare products Regulatory Agency has revealed its new delivery plan, outlining its ...
Posted by Michael Wonder on 24 Jun 2021
ALS association wants more commitment from the FDA
24 June 2021 - In a response letter to the ALS Association, the U.S. FDA has recognised the unmet therapeutic ...
Posted by Michael Wonder on 24 Jun 2021
Moving patient stories highlight opportunities to strengthen our health care systems for all Australians
24 June 2021 - It was an emotional evening among the nearly 200 in-person and online attendees at Parliament House last ...